Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: A multicentre retrospective observational study

Eli Muchtar*, Moshe E. Gatt, Ory Rouvio, Chezi Ganzel, Evgeni Chubar, Celia Suriu, Tamar Tadmor, Olga Shevetz, Noa Lavi, Tzippy Shochat, Yael C. Cohen, Irit Avivi, Pia Raanani, Hila Magen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Carfilzomib has been established in previous years as a treatment for patients with relapsed and/or refractory multiple myeloma (RR-MM). A retrospective multicentre study to evaluate the clinical use of carfilzomib for RR-MM outside of a clinical trial setting was conducted by our group. One hundred and thirty-five patients were included. All patients had been previously exposed to bortezomib and 93% had also been treated with lenalidomide. The vast majority of patients received carfilzomib as part of a two- or three-drug combination. The overall response rate was 47·2%. Multivariate analysis revealed bortezomib resistance, lenalidomide resistance and albumin <35 g/l to negatively impact the likelihood of achieving response. The median duration of response was 8·4 months, and was significantly higher in patients receiving three-drug combination and patients presenting without extramedullary disease. The median progression-free survival and overall survival for the entire cohort was 4·9 months (95% confidence interval [CI] 3·8-6·4) and 12·2 months (95% CI 9-not reached), respectively. Toxicity was manageable, although treatment-related death was seen in 5% of patients. In the setting of progressive multiple myeloma, carfilzomib in a combination regimens yields effective results with a manageable toxicity.

Original languageAmerican English
Pages (from-to)89-96
Number of pages8
JournalBritish Journal of Haematology
Volume172
Issue number1
DOIs
StatePublished - 1 Jan 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016 John Wiley & Sons Ltd.

Keywords

  • Carfilzomib
  • Myeloma
  • Relapse
  • Resistance

Fingerprint

Dive into the research topics of 'Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: A multicentre retrospective observational study'. Together they form a unique fingerprint.

Cite this